Abilify plus an antidepressant for mood disorders
‘The atypical antipsychotic drug Abilify (aripiprazole) appears to enhance the response to antidepressants in patients with treatment-resistant major depression, research suggests.
Atypical antipsychotic agents are often used to augment antidepressants among patients with refractory mood disorders, lead author Dr. George I. Papakostas and colleagues note in their report, published in the Journal of Clinical Psychiatry.
Abilify is unique among the atypical antipsychotics and therefore may be more effective than other drugs in its class. It may also have a better adverse effect profile, Papakostas said in an interview with Reuters Health. ‘
Read more at Abilify plus an antidepressant for mood disorders
Recent Entries
- Sigma Pharmaceuticals year profit rises 27 pct
- South African citizens cheap drug guinea pigs
- Two drugs test victims face a year in coma
- Can drug companies improve their reputation?
- Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
- Pfizer’s Forecast Disappoints
- Pharmaceutical RFID Adoption Stalls
- Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
- GlaxoSmithKline unveils best results since merger
- Pfizer Sues Teva, Sandoz Over Zithromax